Neovascular Glaucoma

Ophthalmology
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
AfliberceptN/A1 trial
Active Trials
NCT04519619Recruiting480Est. Jun 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BayerAflibercept

Clinical Trials (1)

Total enrollment: 480 patients across 1 trials

NCT04519619BayerAflibercept

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Start: Nov 2020Est. completion: Jun 2028480 patients
N/ARecruiting

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 480 patients
1 companies competing in this space